{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:40:22Z","timestamp":1738546822180,"version":"3.35.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/ftd.0b013e31818b0e6a","type":"journal-article","created":{"date-parts":[[2008,11,21]],"date-time":"2008-11-21T08:16:16Z","timestamp":1227255376000},"page":"744-747","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Spironolactone, Potassium Canrenoate and Their Common Metabolite Canrenone on Serum Digoxin Measurement by Digoxin III, a New Digoxin Immunoassay"],"prefix":"10.1097","volume":"30","author":[{"given":"Amitava","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertie","family":"Tso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00316635","article-title":"Difference in metabolic profile of potassium canrenoate and spironolactone in rat: mutagenic metabolites unique to potassium canrenoate.","volume":"61","author":"Cook","year":"1988","journal-title":"Arch Toxicol"},{"key":"R2-16-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1248\/bpb1978.8.161","article-title":"Pharmacokinetics of spironolactone and potassium canrenoate in humans.","volume":"8","author":"Kojima","year":"1985","journal-title":"J Pharmacobiodyn"},{"key":"R3-16-20210129","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-5347(24)06137-8","article-title":"Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope labeling techniques.","volume":"7","author":"Vose","year":"1979","journal-title":"Drug Metab Dispos"},{"key":"R5-16-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","article-title":"Relationship of serum digoxin concentrations to mortality and morbidity in women in the digitalis investigation group trial: a retrospective study.","volume":"46","author":"Adams","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R6-16-20210129","first-page":"787","article-title":"The effects of spironolactone and canrenone in digoxin radioimmunoassay.","volume":"9","author":"Huffman","year":"1974","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"R7-16-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00007691-198901000-00025","article-title":"Interference of spironolactone metabolites in a digoxin radioimmunoassay [Letter].","volume":"11","author":"Crothers","year":"1989","journal-title":"Ther Drug Monit"},{"key":"R8-16-20210129","first-page":"557","article-title":"The effect of oral spironolactone and intravenous canrenoate K on the digoxin radioimmunoassay.","volume":"15","author":"Lichey","year":"1977","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"R9-16-20210129","first-page":"61","article-title":"The influence of intravenous canrenoate on the determination of digoxin in serum by radio and enzyme immunoassay.","volume":"17","author":"Lichey","year":"1979","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"R10-16-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/clinchem\/25.1.48","article-title":"Spironolactone-associated digoxin radioimmunoassay interference.","volume":"25","author":"Silber","year":"1979","journal-title":"Clin Chem"},{"key":"R11-16-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00540949","article-title":"The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay.","volume":"34","author":"Morris","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-16-20210129","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-198903000-00013","article-title":"Reassessment of cross-reactivity of spironolactone metabolites with four digoxin assays.","volume":"11","author":"Pleasants","year":"1989","journal-title":"Ther Drug Monit"},{"key":"R13-16-20210129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00007691-199001000-00015","article-title":"Influence of spironolactone and its metabolite canrenone on serum digoxin assays.","volume":"12","author":"Foukaridis","year":"1990","journal-title":"Ther Drug Monit"},{"key":"R14-16-20210129","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/clinchem\/35.7.1326","article-title":"An update on digoxin.","volume":"35","author":"Stone","year":"1989","journal-title":"Clin Chem"},{"key":"R15-16-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-199712000-00009","article-title":"Cross-reactivity of TDX and OPUS immunoassay system for serum digoxin determination.","volume":"19","author":"Okazaki","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R16-16-20210129","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(99)03818-0","article-title":"Intoxication due to negative canrenone interference in digoxin monitoring [Letter].","volume":"354","author":"Steimer","year":"1999","journal-title":"Lancet"},{"key":"R17-16-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/clinchem\/48.3.507","article-title":"Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone and other steroids.","volume":"48","author":"Steimer","year":"2002","journal-title":"Clin Chem"},{"key":"R18-16-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcla.10039","article-title":"Bidirectional (positive\/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.","volume":"16","author":"Dasgupta","year":"2002","journal-title":"J Clin Lab Anal"},{"key":"R19-16-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0039-128X(89)90078-0","article-title":"6,7-dihydroxy-6,7-dihydrocanrenone isomers: improved synthesis and proton NMR study.","volume":"54","author":"Tal","year":"1989","journal-title":"Steroids"},{"key":"R20-16-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00001503-200212000-00014","article-title":"Therapeutic drug monitoring.","volume":"15","author":"Shenfield","year":"2002","journal-title":"Curr Opin Anaesthesiol"},{"key":"R21-16-20210129","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-98-4-483","article-title":"Anomalous serum digoxin concentration in uremia.","volume":"98","author":"Craver","year":"1983","journal-title":"Ann Intern Med"},{"key":"R22-16-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00007691-199602000-00011","article-title":"Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180.","volume":"18","author":"Miller","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R23-16-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/10408369708998094","article-title":"Digoxin and its related endogenous factors.","volume":"34","author":"Jortani","year":"1997","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R24-16-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/abbi.1996.0160","article-title":"Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissue.","volume":"328","author":"Qazzaz","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"R25-16-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1373\/clinchem.2003.022715","article-title":"De novo biosynthesis and radiolabeling of mammalian digitalis like factors.","volume":"50","author":"Qazzaz","year":"2004","journal-title":"Clin Chem"},{"key":"R26-16-20210129","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.ftd.0000211818.35182.cb","article-title":"Suspected DLIS interference in the dimension DGNA digoxin assay method and clinical application of the revised digoxin target range.","volume":"28","author":"Morris","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R27-16-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady state serum levels of the sulfur containing metabolites.","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R28-16-20210129","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00542109","article-title":"Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.","volume":"25","author":"Karras","year":"1983","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31818b0e6a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:19:08Z","timestamp":1738545548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200812000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31818b0e6a","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}